Преимущества гендерно-нейтральной стратегии вакцинации для профилактики ВПЧ-ассоциированных заболеваний и искоренения ВПЧ-инфекции в целом. Актуальное состояние вакцинации против ВПЧ в мире

Папилломавирусная инфекция (ВПЧ-инфекция) по распространенности занимает лидирующее место среди инфекций, передающихся половым путем. ВПЧ-инфекция и ассоциированные с ней заболевания, в том числе онкологические, остаются одной из глобальных проблем современности. В литературном обзоре представлены актуальные данные зарубежных исследований и отечественных работ о состоянии вакцинации против ВПЧ в мире, об эффективности применения современных вакцин для профилактики ВПЧ-ассоциированных заболеваний, об используемых в настоящее время стратегиях вакцинации и их эффективности. Целью статьи является определение преимуществ гендерно-нейтральной стратегии вакцинации перед приоритетно используемой стратегией вакцинации только девочек при профилактике ВПЧ-ассоциированных заболеваний, в том числе онкологических, а также для искоренения инфекции ВПЧ в целом.

1. Harden ME, Munger K. Human papillomavirus molecular biology. Mutat Res Rev Mutat Res. 2017;772:3-12. doi: 10.1016/j.mrrev.2016.07.002

2. Bacaj P, Burch D. Human Papillomavirus Infection of the Skin. Arch Pathol Lab Med. 2018;142(6):700-705. doi: 10.5858/arpa.2017-0572-RA

3. Luria L, Cardoza-Favarato G. Human Papillomavirus. In: StatPearls. Treasure Island (FL): StatPearls Publishing; January 24, 2021. Available online: https://www.statpearls.com/ArticleLibrary/viewarticle/23034. Accessed on July 6, 2021.

4. Steinbach A, Riemer AB. Immune evasion mechanisms of human papillomavirus: An update. Int J Cancer. 2018;142(2):224-229. doi: 10.1002/ijc.31027

5. Egawa N, Egawa K, Griffin H, Doorbar J. Human Papillomaviruses; Epithelial Tropisms, and the Development of Neoplasia. Viruses. 2015;7(7):3863-3890. doi: 10.3390/v7072802

6. Bravo IG, Felez-Sanchez M. Papillomaviruses: Viral evolution, cancer and evolutionary medicine. Evol Med Public Health. 2015;2015(1):32-51. doi: 10.1093/emph/eov003

7. Nunes EM, Talpe-Nunes V, Sichero L. Epidemiology and biology of cutaneous human papillomavirus. Clinics (Sao Paulo). 2018;73(Suppl 1):e489s. doi: 10.6061/clinics/2018/e489s

8. Egawa N, Doorbar J. The low-risk papillomaviruses. Virus Res. 2017;231:119-127. doi: 10.1016/j.virusres.2016.12.017

9. Papillomavirus Episteme (PaVE): A resource of the Bioinformatics and Computational Biosciences Branch at the National Institute of Allergy and Infectious Diseases (NIAID) Office of Cyber Infrastructure and Computational Biology. Available online: https://pave.niaid.nih.gov. Accessed on March 30, 2021.

10. Bedell SL, Goldstein LS, Goldstein AR, Goldstein AT. Cervical Cancer Screening: Past, Present, and Future. Sex Med Rev. 2020;8(1):28-37. doi: 10.1016/j.sxmr.2019.09.005

11. Kobayashi K, Hisamatsu K, Suzui N, Hara A, Tomita H, Miyazaki T. A Review of HPV-Related Head and Neck Cancer. J Clin Med. 2018;7(9):241. doi: 10.3390/jcm7090241

12. Timbang MR, Sim MW, Bewley AF, Farwell DG, Mantravadi A, Moore MG. HPV-related oropharyngeal cancer: a review on burden of the disease and opportunities for prevention and early detection. Hum Vaccin Immunother. 2019;15(7-8):1920-1928. doi: 10.1080/21645515.2019.1600985

13. Spence T, Bruce J, Yip KW, Liu FF. HPV Associated Head and Neck Cancer. Cancers (Basel). 2016;8(8):75. doi: 10.3390/cancers8080075

14. Bratman SV, Bruce JP, O'Sullivan B, et al. Human Papillomavirus Genotype Association With Survival in Head and Neck Squamous Cell Carcinoma. JAMA Oncol. 2016;2(6):823-826. doi: 10.1001/jamaoncol.2015.6587

15. Wittekindt C, Wagner S, Sharma SJ, et al. HPV — A different view on Head and Neck Cancer. Laryngorhinootologie. 2018;97(S 01):S48-S113. doi: 10.1055/s-0043-121596

16. Stratton KL, Culkin DJ. A Contemporary Review of HPV and Penile Cancer. Oncology (Williston Park). 2016;30(3):245-249.

17. Berman TA, Schiller JT. Human papillomavirus in cervical cancer and oropharyngeal cancer: One cause, two diseases. Cancer. 2017;123(12):2219-2229. doi: 10.1002/cncr.30588

18. Ilboudo M, Zohoncon TM, Traore IMA, et al. Implication of low risk human papillomaviruses, HPV6 and HPV11 in laryngeal papillomatosis in Burkina Faso. Am J Otolaryngol. 2019;40(3):368-371. doi: 10.1016/j.amjoto.2019.02.003

19. National Cancer Institute. The Surveillance, Epidemiology, and End Results (SEER). Available online: https://seer.cancer.gov/sta-tistics. Accessed on March 30, 2021.

20. World Health Organization International Agency for Research on Cancer. Global Cancer Observatory. Available online: https://gco.iarc.fr. Accessed on March 30, 2021.

21. Van Dyne EA, Henley SJ, Saraiya M, Thomas CC, Markowitz LE, Benard VB. Trends in Human Papillomavirus-Associated Cancers — United States, 1999-2015. MMWR Morb Mortal Wkly Rep. 2018;67(33):918-924. doi: 10.15585/mmwr.mm6733a2

22. World Health Organization. Recomendations for routine immunization (updated: September 2020) Available online: http://www.who.int/immunization/policy/Immunization_routine_table1.pdf Accessed on February 20, 2021.

23. Chan CK, Aimagambetova G, Ukybassova T, Kongrtay K, Azizan A. Human Papillomavirus Infection and Cervical Cancer: Epidemiology, Screening, and Vaccination-Review of Current Perspectives. J Oncol. 2019;2019:3257939. doi: 10.1155/2019/3257939

24. Schiller J, Lowy D. Explanations for the high potency of HPV prophylactic vaccines. Vaccine. 2018;36(32 Pt A):4768-4773. doi: 10.1016/j.vaccine.2017.12.079

25. Stanley M, Dull P HPV single-dose vaccination: Impact potential, evidence base and further evaluation. Vaccine. 2018;36(32 Pt A):4759-4760. doi: 10.1016/j.vaccine.2018.02.076

26. Schiller JT, Castellsague X, Garland SM. A review of clinical trials of human papillomavirus prophylactic vaccines. Vaccine. 2012;30 Suppl 5(0 5):F123-F138. doi: 10.1016/j.vaccine.2012.04.108

27. Handler NS, Handler MZ, Majewski S, Schwartz RA. Human papillomavirus vaccine trials and tribulations: Vaccine efficacy. J Am Acad Dermatol. 2015;73(5):759-768. doi: 10.1016/j.jaad.2015.05.041

28. Joura EA, Giuliano AR, Iversen OE, et al. A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. N Engl J Med. 2015;372(8):711-723. doi: 10.1056/NEJMoa1405044

29. Vesikari T, Brodszki N, van Damme P, et al. A Randomized, Double-Blind, Phase III Study of the Immunogenicity and Safety of a 9-Valent Human Papillomavirus L1 Virus-Like Particle Vaccine (V503) Versus Gardasil® in 9-15-Year-Old Girls. Pediatr Infect Dis J. 2015;34(9):992-998. doi: 10.1097/INF.0000000000000773

30. Nyg rd M, Saah A, Munk C, et al. Evaluation of the Long-Term Anti-Human Papillomavirus 6 (HPV6), 11, 16, and 18 Immune Responses Generated by the Quadrivalent HPV Vaccine. Clin Vaccine Immunol. 2015;22(8):943-948. doi: 10.1128/CVI.00133-15

31. Brotherton JML. Impact of HPV vaccination: Achievements and future challenges. Papillomavirus Res. 2019;7:138-140. doi: 10.1016/j.pvr.2019.04.004

32. Резолюция совета экспертов «Папилломавирусная инфекция: обзор накопленного опыта в решении мультидисциплинарной проблемы» // Эпидемиология и Вакцинопрофилактика. — 2018. — Т. 17. — № 6. — С. 109-113.

33. Tanaka H, Shirasawa H, Shimizu D, et al. Preventive effect of human papillomavirus vaccination on the development of uterine cervical lesions in young Japanese women. J Obstet Gynaecol Res. 2017;43(10):1597-1601. doi: 10.1111/jog.13419

34. World Health Organization. Progress and Challenges with Achieving Universal Immunization Coverage 2019 (data as July 2020). Available online: https://www.who.int/immunization/moni-toring_surveillance/who-immuniz.pdf. Accessed on February 20, 2021.

35. Sheikh S, Biundo E, Courcier S, et al. A report on the status of vaccination in Europe [published correction appears in Vaccine. 2019 Feb 28;37(10):1374-1376]. Vaccine. 2018;36(33):4979-4992. doi: 10.1016/j.vaccine.2018.06.044

36. Toh ZQ, Russell FM, Garland SM, Mulholland EK, Patton G, Licciardi PV. Human Papillomavirus Vaccination After COVID-19. JNCI Cancer Spectr. 2021;5(2):pkab011. doi: 10.1093/jncics/pkab011

37. Gavi. Overview of COVID-19 Situation in GAVI-Supported Countries and GAVI’s Response 30th June 2020. Available online: https://www.gavi.org/vaccineswork/30-june-2020-overview-covid-19-situation-gavi-supported-countries-gavi-response. Accessed on March 30, 2021.

38. Девятилова А.Н. Возможности профилактики и ранней диагностики рака шейки матки на региональном уровне // Смоленский медицинский альманах. — 2019. — № 1. — С. 95-97. [Devyatilova AN. Possibilities of prevention and early diagnosis of cervical cancer at the regional level. Smolensk medical almanac. 2019;(1):95-97. (In Russ).]

39. Симаходский А.С., Ипполитова М.Ф. Опыт формирования и реализации региональной программы иммунизации детского населения Санкт-Петербурга против папилломавирусной инфекции // Эпидемиология и Вакцинопрофилактика. — 2019. — Т. 18. — № 3. — С. 65-70. [Simakhodsky AS, Ippolitova MF. Experience of Formation and Implementation of the Regional Program of Immunization of Children's Population of St. Petersburg against Papillomavirus Infection. Epidemiology and Vaccinal Prevention. 2019;18(3):65-70. (In Russ).] doi: 10.31631/2073-3046-2019-18-3-65-70

40. Филиппов О.В., Большакова Л.Н., Елагина Т.Н., Новикова Ю.Б., Шаповалова РФ., Аристова А.М. Региональный календарь профилактических прививок в Москве: история, развитие, перспективы // Эпидемиология и Вакцинопрофилактика. — 2020. — Т. 19. — № 4. — С. 63-75. doi: 10.31631/2073-3046-2020-19-4-63-75

41. Williams WW, Lu PJ, O'Halloran A, et al. Surveillance of Vaccination Coverage among Adult Populations — United States, 2015. MMWR Surveill Summ. 2017;66(11):1-28. doi: 10.15585/mmwr.ss6611a1

42. Skufca J, Ollgren J, Artama M, Ruokokoski E, Nohynek H, Palmu AA. The association of adverse events with bivalent human papilloma virus vaccination: A nationwide register-based cohort study in Finland. Vaccine. 2018;36(39):5926-5933. doi: 10.1016/j.vaccine.2018.06.074

43. Public Health England. Human papillomavirus (HPV) vaccination coverage in adolescent females in England: 2018/19: Report for England. Avaliable online: https://assets.publishing.service. gov.uk/government/uploads/system/uploads/attachment_data/file/851797/HPV_annual_coverage_report_2018_to_2019.pdf. Accessed on March 30, 2021.

44. Walker TY, Elam-Evans LD, Yankey D, et al. National, Regional, State, and Selected Local Area Vaccination Coverage Among Adolescents Aged 13-17 Years — United States, 2018. MMWR Morb Mortal Wkly Rep. 2019;68(33):718-723. doi: 10.15585/mmwr.mm6833a2

45. Bogaards JA, Wallinga J, Brakenhoff RH, Meijer CJ, Berkhof J. Direct benefit of vaccinating boys along with girls against oncogenic human papillomavirus: bayesian evidence synthesis. BMJ. 2015;350:h2016. doi: 10.1136/bmj.h2016

46. Vanska S, Luostarinen T, Baussano I, et al. Vaccination With Moderate Coverage Eradicates Oncogenic Human Papillomaviruses If a Gender-Neutral Strategy Is Applied. J Infect Dis. 2020;222(6):948-956. doi: 10.1093/infdis/jiaa099

47. Faust H, Toft L, Sehr P, et al. Human Papillomavirus neutralizing and cross-reactive antibodies induced in HIV-positive subjects after vaccination with quadrivalent and bivalent HPV vaccines. Vaccine. 2016;34(13):1559-1565. doi: 10.1016/j.vaccine.2016.02.019

48. Lehtinen M, Luostarinen T, Vanska S, et al. Gender-neutral vaccination provides improved control of human papillomavirus types 18/31/33/35 through herd immunity: Results of a community randomized trial (III). Int J Cancer. 2018;143(9):2299-2310. doi: 10.1002/ijc.31618

49. Drolet M, Benard Ё, Boily MC, et al. Population-level impact and herd effects following human papillomavirus vaccination programmes: a systematic review and meta-analysis. Lancet Infect Dis. 2015;15(5):565-580. doi: 10.1016/S1473-3099(14)71073-4

50. Cameron RL, Kavanagh K, Pan J, et al. Human Papillomavirus Prevalence and Herd Immunity after Introduction of Vaccination Program, Scotland, 2009-2013. Emerg Infect Dis. 2016;22(1):56-64. doi: 10.3201/eid2201.150736

51. Brisson M, Benard Ё, Drolet M, et al. Population-level impact, herd immunity, and elimination after human papillomavirus vaccination: a systematic review and meta-analysis of predictions from transmission-dynamic models. Lancet Public Health. 2016;1(1):e8-e17. doi: 10.1016/S2468-2667(16)30001-9

52. Elfstrom KM, Lazzarato F, Franceschi S, Dillner J, Baussano I. Human Papillomavirus Vaccination of Boys and Extended Catchup Vaccination: Effects on the Resilience of Programs. J Infect Dis. 2016;213(2):199-205. doi: 10.1093/infdis/jiv368

53. Chow EPF, Machalek DA, Tabrizi SN, et al. Quadrivalent vaccine-targeted human papillomavirus genotypes in heterosexual men after the Australian female human papillomavirus vaccination programme: a retrospective observational study [published correction appears in Lancet Infect Dis. 2017 Jan;17 (1):17]. Lancet Infect Dis. 2017;17(1):68-77. doi: 10.1016/S1473-3099(16)30116-5

54. Spinner C, Ding L, Bernstein DI, et al. Human Papillomavirus Vaccine Effectiveness and Herd Protection in Young Women. Pediatrics. 2019;143(2):e20181902. doi: 10.1542/peds.2018-1902

55. Machalek DA, Chow EP Garland SM, et al. Human Papillomavirus Prevalence in Unvaccinated Heterosexual Men After a National Female Vaccination Program. J Infect Dis. 2017;215(2):202-208. doi: 10.1093/infdis/jiw530

56. Kavanagh K, Pollock KG, Cuschieri K, et al. Changes in the prevalence of human papillomavirus following a national bivalent human papillomavirus vaccination programme in Scotland: a 7-year cross-sectional study. Lancet Infect Dis. 2017;17(12):1293-1302. doi: 10.1016/S1473-3099(17)30468-1

57. Novakovic D, Cheng ATL, Zurynski Y, et al. A Prospective Study of the Incidence of Juvenile-Onset Recurrent Respiratory Papillomatosis After Implementation of a National HPV Vaccination Program. J Infect Dis. 2018;217(2):208-212. doi: 10.1093/infdis/jix498

58. Lehtinen M, Soderlund-Strand A, Vanska S, et al. Impact of gender-neutral or girls-only vaccination against human papillomavirus-Results of a community-randomized clinical trial (I). Int J Cancer. 2018;142(5):949-958. doi: 10.1002/ijc.31119